Neil Gunn
Vermögen: 538 382 $ am 31.05.2026
Vermögen: 538 382 $ am 31.05.2026
Dr. Neil Gunn is an Independent Director at NeoGenomics, Inc., an Independent Director at Rarecells, Inc. and an Independent Director at Alveo Technologies, Inc. He is on the Board of Directors at NeoGenomics, Inc., Rarecells, Inc., Alveo Technologies, Inc. and Rarecells Diagnostics SAS. Dr. Gunn was previously employed as a Chief Executive Officer & Director by IDbyDNA, Inc., a Non-Executive Director by Genetic Signatures Ltd., a President by Roche Sequencing Solutions, Inc., a Vice President-Commercial Operations by CaridianBCT, Inc., a Vice President-Commercial Operations by Novartis Vaccines & Diagnostics SL, and a Head-Global Business by Roche Molecular Systems, Inc. He received his undergraduate degree from Nottingham Trent University, a graduate degree from the University of Portsmouth and a doctorate degree from the University of Portsmouth.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NEOGENOMICS, INC. 0,04 % | 01.06.2026 | 51 177 ( 0,04 % ) | 538 382 $ | 31.05.2026 |
| 08.05.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| NEOGENOMICS, INC. | Direktor/Vorstandsmitglied | 26.06.2023 |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices | Direktor/Vorstandsmitglied | 13.05.2021 |
Rarecells USA, Inc.
Rarecells USA, Inc. Packaged SoftwareTechnology Services Develops and commercializes technology to isolate circulating cancer cells for early cancer diagnosis and medical research | Direktor/Vorstandsmitglied | 06.09.2022 |
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Develops and commercializes ISET technology to isolate circulating cancer cells for early cancer diagnosis & medical research | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| GENETIC SIGNATURES LIMITED | Vorstandsvorsitzender | 30.09.2024 |
IDbyDNA, Inc.
IDbyDNA, Inc. BiotechnologyHealth Technology Develops technologies that will enable nucleic acid based identification testing services | Vorstandsvorsitzender | 01.01.2022 |
CaridianBCT, Inc.
CaridianBCT, Inc. Medical/Nursing ServicesHealth Services Designs, develops and supplies blood components | Corporate Officer/Principal | - |
Novartis Vaccines & Diagnostics SL | Corporate Officer/Principal | - |
Roche Molecular Systems, Inc.
Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Develops & produces molecular-based diagnostic tests & automated testing platforms | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 12 |
|---|---|
NeoGenomics, Inc.
NeoGenomics, Inc. Medical/Nursing ServicesHealth Services Provides genetic and molecular testing services | Health Services |
Nottingham Trent University
Nottingham Trent University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CaridianBCT, Inc.
CaridianBCT, Inc. Medical/Nursing ServicesHealth Services Designs, develops and supplies blood components | Health Services |
Genetic Signatures Ltd.
Genetic Signatures Ltd. Miscellaneous Commercial ServicesCommercial Services Develops and commercializes diagnostic kits | Commercial Services |
University of Portsmouth
University of Portsmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Molecular Systems, Inc.
Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Develops & produces molecular-based diagnostic tests & automated testing platforms | Health Services |
Novartis Vaccines & Diagnostics SL | |
Rarecells USA, Inc.
Rarecells USA, Inc. Packaged SoftwareTechnology Services Develops and commercializes technology to isolate circulating cancer cells for early cancer diagnosis and medical research | Technology Services |
IDbyDNA, Inc.
IDbyDNA, Inc. BiotechnologyHealth Technology Develops technologies that will enable nucleic acid based identification testing services | Health Technology |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices | Health Technology |
Roche Sequencing Solutions, Inc.
Roche Sequencing Solutions, Inc. Medical/Nursing ServicesHealth Services Provides diagnostics and treatments services | Health Services |
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Develops and commercializes ISET technology to isolate circulating cancer cells for early cancer diagnosis & medical research | Technology Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen